Febit said this week that it is now offering whole-genome sequencing services in Europe for a wide range of species, using the Applied Biosystems SOLiD platform. The new offer complements the firm's existing targeted resequencing, whole-transcriptome sequencing, and small DNA sequencing services on the SOLiD.
The service includes "ultra-deep" resequencing with high coverage for the detection of SNPs, insertions, deletions, inversions, and translocations.
Pricing for human genome sequencing will start at €9,750 ($13,200) for a minimum order of 100 human genomes. For each genome, Febit will generate between 80 and 90 gigabases of mappable sequence data with 50-base mate pair reads.
The company owns two SOLiD systems, one of which is dedicated to service work, the other one to internal research and development.
Ambry Genetics this week launched the Ambry X-Linked Mental Retardation SuperPanel, a suite of genetic tests for X-linked and other mental retardation that uses next-generation sequencing, microarrays, Sanger sequencing, and traditional Fragile X testing.
Part of the test package is an XLMR Next Gen Sequencing Panel that uses RainDance Technologies' RDT 1000 system to enrich DNA for sequencing with the Illumina GAIIx.
Testing can be customized for individual patients.
LC Sciences said last week that it has launched Seq-Array services that couple deep sequencing with customized microarrays for microRNA research.
Seq-Array for microRNA starts with small RNA deep sequencing of a single RNA sample or a mix of samples to generate a list of microRNAs. Company researchers map the sequence reads to a custom-generated sequence database, classify and align all sequences and sequence variants, and predict novel microRNAs. Based on the results, as well as already available microRNA data, they then design a custom SeqArray microarray, which they use to profile the expression of these microRNAs in large numbers of samples.